PATENT CLAIM ANALYSIS

Application Number: 16382726
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-10
Patent Classification: ["514", "049000"]

Abstract:
Methods for treating cancer by administration of two or more therapeutic agents are provided. The two or more therapeutic agents include a cyclin-dependent kinase inhibitor (e.g., alvocidib) and an anthracycline (e.g., daunorubicin or idarubicin). Kits comprising the two or more therapeutic agents that can be used to perform such methods are also provided.

Claim (Index 4):
The method of  claim 1 , wherein the hematologic cancer is multiple myeloma, myelodysplastic syndrome, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), acute lymphocytic leukemia, chronic lymphogenous leukemia, chronic lymphocytic leukemia (CLL), mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, or non-Hodgkin's lymphoma.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 100.0
- Lexical Diversity: 1.44186
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12730097', '11811626', '12032583', '14315930', '14009021']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7506978001849469
- 35 USC 102 Novelty (BERT): 0.5272801743880419
- Combined Prediction Score: 0.7283560376052565
- Mean Citation Score: 273.01801600000005
- Max Citation Score: 319.75333
- Similarity Product: 244.62516767038943

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test